ERT Sets New Standard for Centralized Cardiac Safety Monitoring

News provided by

ERT

Feb 28, 2019, 09:00 ET


PHILADELPHIA (PRWEB) February 28, 2019 -- ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced an advanced Business Intelligence suite for Cardiac Safety monitoring to reduce data variation, protect patients, and instill more confidence in clinical trial outcomes.

ERT’s new Business Intelligence suite for Cardiac Safety provides actionable insight into study performance through near real-time data access in a centralized, easy-to-use environment. Sponsors can immediately access detailed study data with insight into lead reversals, interference and signal noise. They can also triangulate cardiac safety and compliance data with specific sites to help immediately course-correct when certain patterns emerge.

"ERT’s methodology for centralized cardiac safety monitoring has been proven to reduce data variation up to 30% compared to outdated, decentralized machine-recorded measurements at sites,” said Ellen Street, Executive Vice President, Cardiac Safety, ERT. “By layering advanced Business Intelligence onto ERT’s existing solution, clinical trial sponsors can be even more confident in their outcomes while protecting the value of their assets and keeping patients safer during clinical development.”

Study data are housed and mastered in ERT’s proprietary operational data store (ODS), a cloud-based, scalable data platform that enables ERT to efficiently ingest any type of data from any source ─ including 3rd party systems ─ for reporting in near real-time, and serves as the foundation for all of ERT’s ongoing and future product development initiatives.

For more information, visit https://www.ert.com/business-intelligence-suite-for-cardiac-safety/.

About ERT

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials. ERT’s solutions measure treatment efficacy, ensure patient safety, enable effective data integration and analytics, and deliver real-world insights so that its customers can move ahead with confidence.

Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions in 15,000+ studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables its customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.

Christine Tobin, ERT, http://www.ert.com, +1 4127194568, [email protected]